www.techtimes.com
CRISPR Sickle Cell Therapy Now Cleared for Children Starting at Age Two
Casgevy sickle cell gene therapy is now FDA-approved for children as young as two, opening access for 5,500 more U.S. kids. The July 2026 expansion brings a CRISPR-based cure within reach earlier —...
Leggi l'articolo su www.techtimes.com